The connectivity between IL-12 and CXCL9 seen in the networks from mildly symptomatic patients is also observed in the context of cancer therapy, in which administration of IL-12 increases the expression of CXCL9 in peripheral blood mononuclear cells as a response against the tumour [31,32]. Here, CXCL9 is linked to cancer.